US 11,739,063 B2
DREADD actuators
Jordi Bonaventura, Baltimore, MD (US); Juan Luis Gomez, Frederick, MD (US); Andrew Horti, Ellicott City, MD (US); Feng Hu, Lutherville, MD (US); Michael Michaelides, Baltimore, MD (US); Martin Pomper, Baltimore, MD (US); and Marta Sanchez-Soto, Odenton, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and The Johns Hopkins University, Baltimore, MD (US)
Appl. No. 16/968,437
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and The Johns Hopkins University, Baltimore, MD (US)
PCT Filed Feb. 6, 2019, PCT No. PCT/US2019/016892
§ 371(c)(1), (2) Date Aug. 7, 2020,
PCT Pub. No. WO2019/157083, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/627,527, filed on Feb. 7, 2018.
Prior Publication US 2020/0399228 A1, Dec. 24, 2020
Int. Cl. C07D 243/38 (2006.01); A61K 49/10 (2006.01)
CPC C07D 243/38 (2013.01) [A61K 49/10 (2013.01)] 16 Claims
 
1. A method of reducing locomotor activity in a subject in need thereof comprising administering a compound of, or a pharmaceutically acceptable salt thereof, to the subject, wherein the compound is of formula (III)

OG Complex Work Unit Chemistry
wherein R1 is fluoro, bromo, or iodo, and R3 is methyl or ethyl, or a pharmaceutically acceptable salt thereof.